Background: Myopia is increasingly prevalent worldwide, with projections indicating that nearly 50% of the global population may have myopia by 2050. This surge poses significant concerns due to its impact on vision and quality of life and its link to a range of blinding diseases, including myopic macular degeneration, glaucoma, and retinal detachment. Current pharmacologic and optical interventions offer limited effectiveness in slowing myopia progression, highlighting the urgent need for more effective treatments.
Objective: This study aims to examine the combined effect of bright light therapy and low-dose atropine on myopic progression.
Methods: This is a single-site, 2-arm, single-masked (examiner-masked) randomized controlled trial to compare the effectiveness of low-dose atropine alone and its combination with bright light therapy in retarding myopia progression. The study protocol has been approved by the institutional review boards of Hong Kong Polytechnic University (HSEARS 20180829002-05) and the University of Hong Kong and Hospital Authority Hong Kong West Cluster (UW 20-362). Schoolchildren with myopia aged 7 to 12 years who have not undergone any previous myopic control intervention will be recruited and randomly allocated into 2 groups (n=67 per group) after baseline measurements. Both groups will receive 0.01% atropine twice daily for 24 months. The combination treatment group will also receive a high-intensity lamp for bright light therapy. The primary and secondary outcome measures will be the changes in cycloplegic autorefraction in spherical equivalent refraction and axial length, respectively, measured every 6 months over 2 years from baseline.
Results: The project was funded in January 2019. The recruitment process started on March 21, 2023, and was completed on February 2, 2024. Data collection is expected to be completed in April 2026.
Conclusions: This study will provide new information on whether the combination of bright light therapy and low-dose atropine is more effective than atropine alone in slowing down myopia progression. It will also assess the effectiveness of low-dose atropine used twice daily. Combining bright light therapy and atropine could become a new treatment option if shown to be effective. New data on the effectiveness of using atropine twice daily might also expand available treatment options.
Keywords: atropine; bright light; clinical trial; myopia; myopia control; refractive errors; vision.
© Dennis Yan-Yin Tse, Martin Ming-Leung Ma, Ying Hon, Lai Ming Ho, Wai Ching Lam, Kendrick Co Shih, Xiujuan Zhang, Desmond Man Kit Lam, Andy Chi Wai Kong, Thomas Chuen Lam, Carly Siu Yin Lam, Tina Jinxiao Lian, Ian Morgan, Chi Ho To, Rachel Ka Man Chun, Christopher Kai Shun Leung. Originally published in JMIR Research Protocols (https://www.researchprotocols.org).